Experts
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Telix Pharmaceuticals.
RELATED STOCKHEAD STORIES
Experts
ScoPo’s Health Powerplays: The money keeps flowing for the ASX biotechs
Health & Biotech
First patients dosed in trial of Telix’s cancer imaging therapy
Health & Biotech
All of 1300 Smiles’ Jobkeeper subsidy has gone on its dividend
Experts
Scopo’s powerplays: Strap yourselves in for some M&A
Health & Biotech
Althea becomes first local cannabis player to launch online sales channel
Experts
Scopo’s health powerplays: Markets are getting back to normal
Health & Biotech
MedAdvisor eyes off US health insurance market with new distribution deal
Health & Biotech
Health: Medlab proves pot reduces a very specific kind of cancer pain
Health & Biotech
Health: Jumbo adds MS, subtracts margins
Health & Biotech
Brain health is complicated, but these ASX small caps are trying to keep it in shape
Health & Biotech
Cancer Wars Part 1: These are the ASX small cap drugmakers that want to conquer cancer
Health & Biotech
Health: Invion may have found its break in Chinese dermatology
Health & Biotech
Health: Gut treatment progress gives Anatara a 24pc boost
Health & Biotech
Health: Is this the big news from Germany Pharmaxis was waiting for?
Health & Biotech
Biotech exec pay — are they delivering returns that equal their pay packets?
Escrow Watch
Escrow Watch: 300 million shares are marching onto the ASX this fortnight
Health & Biotech
